Emplicure AB Interim Report Q2 2022
2022-08-18 06:30
There is great interest in our unique patented bioceramic technology, which provides the opportunity to develop the next generation of nicotine pouches.
Second quarter, April-June 2022
- Net sales amounted to MSEK 0.0 (0.1)
- Operating loss (EBIT) amounted to MSEK -8.7 (-6.5)
- Net loss amounted to MSEK -8.7 (-7.9)
- Net cash flow amounted to MSEK +3.8 (-6.2)
- EPS before and after dilution amounted to SEK -0.37 (-0.68)
January-June 2022
- Net sales amounted to MSEK 0.0 (0.1)
- Operating loss (EBIT) amounted to -16.0 (-7.5)
- Net loss amounted to MSEK -16.0 (-9.3)
- Net cash flow amounted to MSEK -1.7 (+3.3)
- EPS before and after dilution amounted to SEK -0.73 (-0.80)
This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The informationen was submitted for publication, through the agency of the contact persons above, on August 18, 2022 at 08:30 CET.
For more information, please contact:
Torbjörn W. Larsson
CEO
Phone: +46 (0)70 747 65 99
Email: torbjorn.walkerlarsson@emplicure.com
Erik Magnusson
CFO, Investor Relations
Phone: +46 (0)708 565 245
Email: erik.magnusson@emplicure.com
Adviser
Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via ca@mangold.se
The following documents can be retrieved from beQuoted
PM-Emplicure-AB-Q2-Report-2022.pdf
Emplicure-Interim-Report-Q2-2022-ENG.pdf
Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. Wholly owned subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com